Synapse
⌘+K
Synapse
PulseExploreClubsResearchersJournals
Instagram
HomeClubsExplore
December 8, 2025BloodOpen Access

Oncogenic ASPP2κ: A novel regulator of drug resistance and tumor progression in multiple myeloma

View Full Paper
Ask AI
Bookmark
Share

Authors

RHReka A. HarasztiCDChristoph Driessen

Discussion

Loading...

Member takes

Overview

Observational analysis reveals oncogenic ASPP2κ promotes drug resistance in multiple myeloma, suggesting a new therapeutic target.

Key Points

  • Tumor progression is associated with oncogenic ASPP2κ, impacting patient survival rates.
  • Clinically, melphalan treatment in multiple myeloma revealed ASPP2κ as a key regulator in drug resistance.
  • Targeting the TP53 tumorsuppressor and its pathway may enhance efficacy of current chemotherapy regimens.
  • Consequently, targeting ASPP2κ could provide a promising avenue for therapeutics against multiple myeloma.

Cite This Study

Haraszti et al. (2025) studied this question.

synapsesocial.com/papers/69362f484fa91c937236d668https://doi.org/10.1182/blood-2025-5729
View Full Paper
Ask AI
Bookmark
Share

Also Consider

Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context:

  1. 1Single-cell and bulk transcriptomics uncovers PRKD2-driven tumor stemness and progression in multiple myeloma2025 · 1 citations
  2. 2KPNA2 enhances autophagy through activation of the non-canonical NF-κB signaling pathway, thereby promoting the induction of bortezomib resistance in multiple myeloma2025
  3. 3Synthetic lethal targeting of PSMC2-dependent p97-adapted proteasome complexes that confer chemoresistance in multiple myeloma2025 · 1 citations
  4. 4Novel Autoregulation of PIM2 Expression Sustains Plasma Cell Survival in Multiple Myeloma 29162025
  5. 5Integrative omics analysis of TP53 in multiple myeloma patients2025